Eliminate ungrounded scientific claims, mathematical vulnerabilities, and patent infringement liabilities before deploying institutional capital.
We inspect underlying source code, neural topologies, and mathematical formulations for reproducibility, adversarial stability, and zero-hallucination guarantees.
For biotech and molecular ventures: independent re-docking of candidates into target kinase/receptor sites, cardiosafety antitarget screening, and pharmacokinetic clearance modeling.
Exhaustive search across USPTO, EPO, and WIPO classifications to verify claim robustness, Markush genus defensibility, and absence of prior-art infringement.
Rigorous capital allocation analysis: evaluating pre-clinical timeline realism, synthesis cost per gram, assay milestones, and Phase I/IIa regulatory pathways.
Fee: $17,500. Delivery in 10 business days with executive sign-off from Wrocław HQ and our RI Directorate.